Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CB-1 Targeters For Obesity Dropping Fast

This article was originally published in The Pink Sheet Daily

Executive Summary

Psychiatric risk makes Merck’s taranabant the latest casualty.
Advertisement

Related Content

Orexigen Starts Partnership Talks On Obesity Drug Contrave
Orexigen Starts Partnership Talks On Obesity Drug Contrave
Obesity-Focused Zafgen Raises Zaftig Series B
Obesity-Focused Zafgen Raises Zaftig Series B
Pfizer Backs Out Of Cardiovascular R&D
Merck To Focus Taranabant Development On Lower Dose
Merck To Focus Taranabant Development On Lower Dose
Sanofi Withdraws Zimulti NDA For Weight Loss

Topics

Advertisement
UsernamePublicRestriction

Register

PS066899

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel